RESEARCH ARTICLE

Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase

Sandra Berndt1, Vsevolod V. Gurevich1, T. M. Iverson1,2,3,4*

1 Department of Pharmacology, Vanderbilt University, Nashville, TN, United States of America, 2 Department of Biochemistry, Vanderbilt University, Nashville, TN, United States of America, 3 Vanderbilt Institute of Chemical Biology, Nashville, TN, United States of America, 4 Center for Structural Biology, Nashville, TN, United States of America

* tina.iverson@vanderbilt.edu

Abstract

Lyn kinase (Lck/Yes related novel protein tyrosine kinase) belongs to the family of Src-related non-receptor tyrosine kinases. Consistent with physiological roles in cell growth and proliferation, aberrant function of Lyn is associated with various forms of cancer, including leukemia, breast cancer and melanoma. Here, we determine a 1.3 Å resolution crystal structure of the polyproline-binding SH3 regulatory domain of human Lyn kinase, which adopts a five-stranded β-barrel fold. Mapping of cancer-associated point mutations onto this structure reveals that these amino acid substitutions are distributed throughout the SH3 domain and may affect Lyn kinase function distinctly.

Introduction

Lyn kinase (Lck/Yes related novel protein tyrosine kinase) is a Src-family kinase organized into four domains. These include an N-terminal unique domain (also known as SH4 domain), two adapter domains (SH3 and SH2) and C-terminal kinase domain (also known as SH1 domain). Src-family kinase activity is conformationally regulated via distinct interactions between these domains. In the inactive state, the SH3 domain binds to the linker between the SH2 domain and the kinase domain, keeping the kinase in a closed (inactive) conformation [1]. In the active state the SH2 and SH3 domains interact with effectors proteins [2]. This releases the kinase domain and in the resulting open (active) conformation the kinase domain can phosphorylate its substrates [3, 4].

Active Src-family kinases phosphorylate both cytosolic and membrane-anchored proteins. Lyn substrates include, but are not limited to, β-catenin, N-myristoyl transferase 1, and transcription factor Stat3 [5, 6]. The total number of Lyn substrates is not known [7–10] but the physiological impact of substrate phosphorylation by Lyn kinase is cell growth and proliferation [11–13]. SH2 and SH3 adapter domains regulate the interactions of Lyn kinase with substrates and may help confer substrate specificity. Of these, the SH3 domain binds to polyproline sequence motifs (PxxP) in a way that can be recapitulated by peptides [14]. This suggests that the SH3 domain can induce a binding-competent backbone conformation within the region of sequence containing the PxxP motif [15, 16].
Lyn is overexpressed in the hematopoietic cells of patients with acute myeloid leukemia [17], and may be a major drug target for this leukemia type [13]. Lyn overexpression is also observed in colorectal, breast, renal and ovarian cancer [18–21]. Overexpression of Lyn kinase in lung cell carcinoma correlates with poor prognosis [22]. Mutations in Lyn kinase have been found in at least 17 cancer types, including breast, prostate, and liver cancer [23–25]. Due to the role of Lyn kinase in cancer, five Lyn inhibitors (Bosutinib, Ponatinib, Nintedanib, Dasatinib and Bafetinib) are used as therapeutics [26–32], with additional inhibitors, such as Saracatinib, currently in clinical trials [33]. These inhibitors target the active site within the kinase domain [34].

While there is utility in this approach, an additional therapeutic strategy could be the regulation of Lyn kinase activity via the SH3 domain [35]. This strategy requires clear understanding how the structure of the SH3 domain affects kinase activity. NMR structures of the Lyn SH3 domain in the presence and absence of a herpesvirus-derived polyproline-containing peptide previously identified how the Lyn SH3 domain interacts with a high-affinity ligand [36]. Here, we determined the structure of the Lyn SH3 domain to 1.3 Å resolution using X-ray crystallography, which allowed up to propose how cancer-associated point mutations affect this domain.

Materials and methods

2.1 Expression and purification of the human Lyn SH3 domain

E. coli BL21 (DE3) cells were transformed with pDONR223-Lyn (Addgene plasmid # 23905) containing the coding sequence of SH3 domain of Lyn kinase in pET24(+) vector (Novagen). Cells were grown at 37°C in 1 L LB medium containing 100 mg/L ampicillin. At an OD600 of 0.8, expression was induced with 1 mM IPTG and the temperature was lowered from 37°C to 30°C. After 5 h, cells were harvested at 9,180 × g, and the pellet was resuspended in 50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA and 50 mM NaCl (25 ml per 1 L of culture). Protease inhibitor cocktail (Sigma, 600 μl per 1 L cell culture), 2 mM MgCl2 and DNase I (20 U per 1 L of cell culture), 1 mM TCEP, and 100 mg/L lysozyme were added to the suspension. The suspension was sonicated (for 5 sec on/off cycle, 10 min, using a 70% power) and the lysate was centrifuged for 1 h at 4°C at 38,360 × g. The supernatant was passed through a 0.45 μm filter, and loaded on a 5 ml His-Trap HP column equilibrated in wash buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol and 15 mM imidazole). The protein was eluted in wash buffer containing 250 mM imidazole. Protein was further purified by size exclusion chromatography on a Superdex 200 10/300 GL column equilibrated with 20 mM Tris-HCl, pH 7.5, 5% glycerol, 150 mM NaCl, and 1 mM TCEP.

2.2 Crystallization and data collection

Crystals of purified Lyn SH3 domain grew by the hanging drop vapor diffusion method using 1.5 μl of Lyn SH3 domain (10 mg/ml in 20 mM Tris pH 7.5) equilibrated with 1.5 μl of reservoir solution (0.1 M Na citrate pH 3.5, and 3.2 M NaCl) and appeared within 24 h at 22°C. Crystals were cryo-protected using 0.09 M Na citrate pH 3.5, 2.88 M NaCl and 10% glycerol, and were flash cooled by plunging in liquid nitrogen. Data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) Experimental Station 9–2 using a Pilatus 6M detector (Table 1).

2.3 Structure determination, refinement, and analysis

Data were processed using HKL2000 [37] (Table 1) and the structure determined in the Phaser subroutine [38, 39] of PHENIX [40] using the SH3 domain of Lck as the search model [41].
Model improvement used alternating rounds of model building in Coot \cite{42, 43} and refinement in PHENIX \cite{40}. Two distinct positions of the C-terminus (N122 to H126) were observed in the electron density, which likely resulted in higher R-values (Table 1). The model of the C-terminus focused on the conformation with better electron density but could not be modeled with accuracy, and contains two rotameric outliers. Structural superpositions were performed in Coot \cite{42, 43} and figures were rendered in PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC (New York, NY).

**Results and discussion**

**Structure of the Lyn SH3 domain**

Like all Src-family kinases, the multi-domain architecture of Lyn makes the determination of a structure of the full-length protein a significant challenge because the individual domains are predicted to move relative to each other upon kinase activation \cite{44}. Although large, multi-domain fragments of Src, Hck, Lck and Fyn from the Src-family of kinases have been reported \cite{44–48}, structural investigations of Src-family kinases still benefit from the use of isolated domains. For the Lyn kinase, prior structural work includes crystal structures of the kinase domain \cite{49, 50} and the SH2 domain \cite{51} as well as NMR structures of both the unliganded and liganded SH3 domain \cite{36}.

The crystal structure of the Lyn SH3 domain (Fig 1A and 1B) contains five β-strands organized into two β-sheets. Previously termed β1–β5, these β-strands are connected via four loops termed the RT loop, n-src loop, distal loop, and 3₁₀ helical loop. Comparison of our crystal structure with the structure of the unliganded Lyn SH3 domain determined by NMR spectroscopy (PDB 1WIF) \cite{36} yields an RMSD of the Cα atoms of 0.76 Å for residues of the β-barrel and 0.93 Å for all Cα atoms (Fig 2A). The largest differences in position involve the

| Table 1. Data collection and refinement statistics for the Lyn SH3 domain. |  |
|---|---|
| **Data collection statistics** |  |
| SBGrid Entry | 640 |
| Resolution | 1.20 Å |
| Space group | P6₁ |
| Unit-cell dimensions | a = 46.7 Å, b = 46.7 Å, c = 55.7 Å |
| R_{sym} | 0.038 (0.512) |
| R_{pim} | 0.012 (0.171) |
| I/σ | 53.6 (4.00) |
|Completeness (%) | 87.1% (81.8%) |
|Redundancy | 10.5 (9.7) |
|CC₁/₂ | 0.994 (0.923) |
|**Refinement Statistics** |  |
| PDB entry | 6NMW |
| R_{cryst} | 0.172 (0.200) |
| R_{free} | 0.184 (0.251) |
| RMSD bond lengths | 0.014 Å |
| RMSD bond angles | 1.63˚ |
|Ramachandran |  |
| Favored | 100.0% |

https://doi.org/10.1371/journal.pone.0215140.t001
residues that are found within the polyproline binding cleft, G76, H78 and P79 of the RT loop and E98, E99 of n-src loop, which exhibit positional differences of 1.5 Å – 2.3 Å due to rotation of these loop elements. Conformational changes in these two loops are observed in the NMR structure bound to the herpesvirus-derived peptide [36] (Fig 2B and 2C).

Flexibility of the RT and n-src loops has previously been suggested as important for interaction with polyproline motifs, which might proceed via an induced fit mechanism [52–55]. These movements are expected to optimize the contacts between the SH3 domain and the polyproline motif. This could allow for variations on the polyproline sequence motifs that can selectively interact with particular SH3 domains. In the case of the Lyn kinase, physiological partners include PI-3 kinase and Ras-GAP [5, 6]. These binding partners are proposed to alter the position of the SH3 domain in the full-length Src-family kinases, which increases kinase activity.
Cancer-associated mutations

In the absence of a mutation or a protein-protein interaction, the SH3 domain of Src family kinases binds to the kinase domain and inhibits activity [45, 56]. Physiologically, protein-protein interactions with the SH3 domain are believed to move its position so that it no longer inhibits the activity [56, 57]. Thus, the cancer-associated mutations in the Lyn SH3 domain could increase Lyn activity by eliminating this self-inhibition.

| Transformative mutations | Cancer type              | Non-transformative mutations |
|--------------------------|--------------------------|-----------------------------|
| D81N, W99L               | Uterine cancer           | D66Y, K120T                 |
| G76D                     | Sarcoma                  | V68L                        |
| K98N, W99L, A119S        | Thyroid carcinoma        |                             |
| S104F, T107K             | Liver cancer             |                             |
| E98K, S115R, V118M       | Head and neck cancer     | M90I                        |
| E110K                    | Melanoma                 | E95D                        |
|                          | Lung cancer              |                             |
|                          | Malignant glioma         | K108R                       |
|                          | Kidney cancer            | K109T                       |
|                          | Breast cancer            | K120R                       |
|                          | Hematologic cancer       |                             |

Fig 3. Cancer-associated mutations of the Lyn SH3 domain. A. Mutations of 18 out of the 61 amino acids of the Lyn SH3 domain were identified by genome sequencing of patients with the indicated types of cancer [23–25]. The table separates these mutations into likely-transformative and likely non-transformative, based upon prior computational analysis [58]. B. Locations of the likely transformative cancer-associated mutations are shown in red. Locations of the likely non-transformative substitutions are shown in green.

https://doi.org/10.1371/journal.pone.0215140.g003
Advances in sequencing now allow mutations in individual cancer patients to be identified. Analysis of whole genomes revealed 18 cancer-associated point mutations within the Lyn SH3 domain, affecting ~30% of the residues in this domain [23–25] (Fig 3). While cell assays evaluating the impact of these single amino acid changes have not, to date, been reported, the use of computational prediction algorithms suggests that 12 of these substitutions are likely to be transformative and contribute to disease.

Evaluation of the locations of these mutations in the context of the structure suggests that many of the likely transformative substitutions could prevent the interaction of the SH3 domain with the kinase domain, but by distinct mechanisms (Fig 3). For example, a subset of the mutations, including D81N, W99L and E98K, may disrupt the protein-protein interaction interface with the kinase domain, and eliminate negative regulation of kinase activity. Other mutations, such as V118M, may destabilize the fold of the SH3 domain, again preventing the normal attenuation of kinase activity in the basal state of Lyn. In contrast, single amino acid substitutions that are predicted to be non-transformative are either relatively conservative, or are located on the surface of the SH3 domain that is not engaged by the kinase domain.

**Conclusions**

The crystal structure of the Lyn kinase SH3 domain improves the molecular understanding of the regulatory mechanism of the Src family kinases. The mapped cancer-associated mutations in the SH3 domain identify how different regions of this domain affect protein function.

**Acknowledgments**

This work was supported by the National Institutes of Health (NIH) grants GM077561, GM109955 (these two grants were replaced by R35 GM122491) (VVG), GM120569 (TMI), DA043680 (TMI/VVG). This research used resources of the of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393).

**Author Contributions**

**Conceptualization:** T. M. Iverson.

**Data curation:** Sandra Berndt.

**Investigation:** Sandra Berndt.

**Supervision:** Vsevolod V. Gurevich, T. M. Iverson.

**Writing – original draft:** Sandra Berndt.

**Writing – review & editing:** Vsevolod V. Gurevich, T. M. Iverson.

**References**

1. Sicherl F, Kuriyan J. Structures of Src-family tyrosine kinases. Curr Opin Struct Biol. 1997; 7(6):777–85. Epub 1998/01/22. PMID: 9434959.

2. Thomas JW, Ellis B, Boerner RJ, Knight WB, White GC, 2nd, Schaller MD. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem. 1998; 273(1):577–83. Epub 1998/02/07. PMID: 9417118.
3. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 2001; 105(1):115–26. PMID: 11301007.

4. Yadav SS, Miller WT. Cooperative activation of Src family kinases by SH3 and SH2 ligands. Cancer Lett. 2007; 257(1):116–23. Epub 2007/08/28. https://doi.org/10.1016/j.canlet.2007.07.012 PMID: 17719722; PubMed Central PMCID: PMC2045694.

5. Briggs SD, Bryant SS, Jove R, Sanderson SD, Smithgall TE. The Ras GTPase-activating protein (GAP) is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase, Hck. J Biol Chem. 1995; 270(24):14718–24. Epub 1995/06/16. PMID: 7782336.

6. Toubiana J, Rossi AL, Belaidouni N, Grimaldi D, Pene F, Chafey P, et al. Src-family-tyrosine kinase Lyn is critical for TLR2-mediated NF-kappaB activation through the PI 3-kinase signaling pathway. Innate Immun. 2015; 21(7):685–97. Epub 2015/06/10. https://doi.org/10.1177/1753425915586075 PMID: 26055819.

7. Takeda H, Kawamura Y, Miura A, Mori M, Wakamatsu A, Yamamoto J, et al. Comparative analysis of human SRC-family kinase substrate specificity in vitro. J Proteome Res. 2010; 9(11):5982–93. Epub 2010/09/25. https://doi.org/10.1021/pr100773f PMID: 20863140.

8. Orii N, Ganapathiraju MK. Wiki-pi: a web-server of annotated human protein-protein interactions to aid in discovery of protein function. PLoS One. 2012; 7(11):e49029. Epub 2012/12/05. https://doi.org/10.1371/journal.pone.0049029 PMID: 23209562; PubMed Central PMCID: PMC3509123.

9. Orchard S, Ammani M, Aranda B, Breuza L, Broackes-Carter F, et al. The MintAct project—IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014; 42(Database issue):D358–63. Epub 2013/11/16. https://doi.org/10.1093/nar/gkt1115 PMID: 24234451; PubMed Central PMCID: PMC3965093.

10. Chatr-Aryamontri A, Oughtred R, Boucher L, Rust J, Chang C, Kolas NK, et al. The BioGRID interaction database: 2017 update. Nucleic Acids Res. 2017; 45(D1):D369–D79. Epub 2016/12/17. https://doi.org/10.1093/nar/gkw1102 PMID: 27980099; PubMed Central PMCID: PMC5207573.

11. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002; 298(5600):1912–34. Epub 2002/12/10. https://doi.org/10.1126/science.1075762 PMID: 12471243.

12. Lannutti BJ, Drachman JG. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. Blood. 2004; 103(10):3736–43. Epub 2004/01/17. https://doi.org/10.1182/blood-2003-10-3566 PMID: 14726979.

13. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal. 2012; 10(1):21. Epub 2012/07/19. https://doi.org/10.1186/1752-0509-10-21 PMID: 22805580; PubMed Central PMCID: PMC3464935.

14. Songyang Z. Recognition and regulation of primary-sequence motifs by signaling modular domains. Prog Biophys Mol Biol. 1999; 71(3–4):359–72. Epub 1999/06/04. PMID: 10354704.

15. Donaldson LW, Gish G, Pawson T, Kay LE, Forman-Kay JD. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phospho peptide. Proc Natl Acad Sci U S A. 2002; 99(22):14053–8. Epub 2002/10/18. https://doi.org/10.1073/pnas.212518799 PMID: 12384576; PubMed Central PMCID: PMC137835.

16. Morton CJ, Pugh DJ, Brown EL, Kahmann JD, Renzoni DA, Campbell ID. Solution structure and peptide binding of the SH3 domain from human Fyn. Structure. 1996; 4(6):705–14. Epub 1996/06/15. PMID: 8805554.

17. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood. 2008; 111(4):2269–79. Epub 2007/12/07. https://doi.org/10.1182/blood-2007-04-020399 PMID: 18056483.

18. Croucher DR, Hochgrafe F, Zhang L, Liu A, Lyons RJ, Rickwood D, et al. Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway. Cancer Res. 2013; 73(6):1969–78. Epub 2013/02/05. https://doi.org/10.1158/0008-5472.CAN-12-1472 PMID: 23378338.

19. Elsberger B, Fullerton R, Zino S, Jordan F, Mitchell TJ, Brunton VG, et al. Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression. Br J Cancer. 2010; 103(6):899–909. Epub 2010/08/19. https://doi.org/10.1038/sj.bjc.6605829 PMID: 20717116; PubMed Central PMCID: PMC2966624.

20. Kumar G, Breen EJ, Ranganathan S. Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework. BMC Syst Biol. 2013; 7:12. Epub 2013/02/07. https://doi.org/10.1186/1752-0509-7-12 PMID: 23383610; PubMed Central PMCID: PMC3605242.

21. Roseweir AK, Qayyum T, Lim Z, Hammond R, MacDonald AJ, Fraser S, et al. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC
22. Rupniewska E, Roy R, Mauri FA, Liu X, Kaliszczak M, Bellezza G, et al. Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget. 2018; 9(44):27346–62. Epub 2018/06/26. https://doi.org/10.18632/oncotarget.25213 PMID: 29937990; PubMed Central PMCID: PMCPMC6007948.

23. Dingerdissen HM, Torcivia-Rodriguez J, Hu Y, Chang TC, Mazumder R, Kahsay R. BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery. Nucleic Acids Res. 2018; 46(D1):D1128–D36. Epub 2018/07/28. https://doi.org/10.1093/nar/gkx907 PMID: 30053270; PubMed Central PMCID: PMCPMC6007948.

24. Wu TJ, Shamsaddini A, Pan Y, Smith K, Crichton DJ, Simonyan V, et al. A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE). Database (Oxford). 2014; 2014:bau022. Epub 2014/03/29. https://doi.org/10.1093/database/bau022 PMID: 24667251; PubMed Central PMCID: PMCPMC3965850.

25. Wehrle J, von Bubnoff N. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. Recent Results Cancer Res. 2018; 212:109–18. Epub 2018/08/03. https://doi.org/10.1007/978-3-319-91439-8_5 PMID: 30069627.

26. Isfort S, Crysandt M, Gezer D, Keschmieder S, Brummendorf TH, Wolf D. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor. Recent Results Cancer Res. 2018; 212:87–108. Epub 2018/08/03. https://doi.org/10.1007/978-3-319-91439-8_4 PMID: 30069626.

27. Hilberg F, Roth GJ, Krussak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68(12):4774–82. Epub 2008/06/19. https://doi.org/10.1158/0008-5472.CAN-08-0307 PMID: 18595024.

28. McCormack PL. Nintedanib: first global approval. Drugs. 2015; 75(1):129–39. Epub 2014/11/29. https://doi.org/10.1007/s40265-014-0335-0 PMID: 25430078.

29. Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets. 2011; 12(4):563–78. Epub 2011/01/14. PMID: 21226671.

30. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov. 2006; 5(9):717–8. Epub 2006/09/28. https://doi.org/10.1038/nrd2135 PMID: 17001803.

31. Robak P, Robak T. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Curr Med Chem. 2012; 19(31):5294–318. Epub 2012/07/27. PMID: 22830347.

32. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, et al. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015; 33(4):977–84. Epub 2015/06/13. https://doi.org/10.1007/s10637-015-0257-z PMID: 26062928.

33. Tong M, Pelton JG, Gill ML, Zhang W, Picart F, Seeliger MA. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Nat Commun. 2017; 8(1):2160. Epub 2017/12/20. https://doi.org/10.1038/s41467-017-02240-6 PMID: 29255153; PubMed Central PMCID: PMCPMC5735167.

34. Vohidov F, Knudsen SE, Leonard PG, Ohata J, Wheaton MJ, Popp BV, et al. Potent and selective inhibition of SH3 domains with dirhodium metalloinhibitors. Chem Sci. 2015; 6(8):4778–83. Epub 2015/08/01. https://doi.org/10.1039/c5sc01602a PMID: 29142714; PubMed Central PMCID: PMCPMC5667506.

35. Bunkoczi G, Echols N, McCoy AJ, Oeffner RD, Adams PD, Read RJ. Phaser. MRage: automated molecular replacement. Acta Crystallogr D Biol Crystallogr. 2013; 69(Pt 11):2276–86. Epub 2013/11/06. https://doi.org/10.1107/S0907444913022750 PMID: 24189240; PubMed Central PMCID: PMCPMC3817702.
Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase

39. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007; 40(4):658–74. Epub 2007/08/01. https://doi.org/10.1107/S0021889807021206 PMID: 19461840; PubMed Central PMCID: PMCPMC2483472.

40. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):213–21. Epub 2010/02/04. https://doi.org/10.1107/S0907448909052925 PubMed Central PMCID: PMCPMC2815670. PMID: 20124702

41. Romir J, Lilie H, Egerer-Sieber C, Bauer F, Sticht H, Muller YA. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs. J Mol Biol. 2007; 365(5):1417–28. Epub 2006/11/23. https://doi.org/10.1016/j.jmb.2006.10.058 PMID: 17118402.

42. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126–32. Epub 2004/12/02. https://doi.org/10.1107/S0907444904019158 PMID: 15572765.

43. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486–501. Epub 2010/04/13. https://doi.org/10.1107/S0907444910007493 PMID: 20383002; PubMed Central PMCID: PMCPMC2852313.

44. Alvarado JJ, Betts L, Moroco JA, Smithgall TE, Yeh JI. Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. J Biol Chem. 2010; 285(46):35455–61. Epub 2010/09/03. https://doi.org/10.1074/jbc.M110.145102 PMID: 20810664; PubMed Central PMCID: PMCPMC2975169.

45. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 1997; 385(6617):595–602. Epub 1997/02/13. https://doi.org/10.1038/385595a0 PMID: 9246657.

46. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell. 1999; 3(5):629–38. Epub 1999/06/09. PMID: 10360179.

47. Nasetortabi F, Tars K, Becherer K, Kodandapani R, Liljas L, Vuori K, et al. Molecular basis for regulation of Src by the docking protein p130Cas. J Mol Recognit. 2006; 19(1):30–8. Epub 2005/10/26. https://doi.org/10.1002/jmr.755 PMID: 12150857.

48. Williams JC, Weijland A, Gonfoni S, Thomps on A, Courtneidge SA, Superti-Furga G, et al. The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J Mol Biol. 1997; 274(5):757–75. Epub 2000/08/16. https://doi.org/10.1006/jmbi.1997.1433 PMID: 9405157.

49. Miyano N, Kinoshita T, Nakai R, Kirii Y, Yokota K, Tada T. Structural basis for the inhibitor recognition of human Lyn kinase domain. Bioorg Med Chem Lett. 2009; 19(23):6557–60. Epub 2009/10/28. https://doi.org/10.1016/j.bmcl.2009.10.036 PMID: 19857964.

50. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem. 2009; 284(1):284–91. Epub 2008/10/06. https://doi.org/10.1074/jbc.M807850200 PMID: 18984583.

51. Jin LL, Wybenga-Groot LE, Tong J, Taylor P, Minden MD, Trudel S, et al. Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol Cell Proteomics. 2015; 14(3):695–706. Epub 2015/01/15. https://doi.org/10.1074/mcp.M114.044404 PMID: 25587033; PubMed Central PMCID: PMCPMC4399889.

52. Arold S, O’Brien R, Franken P, Strub MP, Hoh F, Dumas C, et al. RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Biochemistry. 1998; 37(42):14683–91. Epub 1998/10/21. https://doi.org/10.1021/bi980989q PMID: 9778343.

53. Martin-Garcia JM, Luque I, Mateo PL, Ruiz-Sanz J, Camara-Artigas A. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation. FEBS Lett. 2007; 581(9):1701–6. Epub 2007/04/10. https://doi.org/10.1016/j.febslet.2007.03.059 PMID: 17418139.

54. Bauer F, Sticht H. A proline to glycine mutation in the Lck SH3-domain affects conformational sampling and increases ligand binding affinity. FEBS Lett. 2007; 581(8):1555–60. Epub 2007/03/27. https://doi.org/10.1016/j.febslet.2007.03.012 PMID: 17382937.

55. Zafra Ruano A, Cilia E, Couceiro JR, Ruiz-Sanz J, Schymkowitz J, Rousseau F, et al. From Binding-Induced Dynamic Effects in SH3 Structures to Evolutionary Conserved Sedors. PLoS Comput Biol. 2016; 12(5):e1004938. Epub 2016/05/24. https://doi.org/10.1371/journal.pcbi.1004938 PMID: 27213566; PubMed Central PMCID: PMCPMC4877006.

56. Moaref I, LaFevre-Bernt M, Sichefi F, Huse M, Lee CH, Kuriyan J, et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 1997; 385(6617):650–3. Epub 1997/02/13. https://doi.org/10.1038/385650a0 PMID: 9024665.
57. Brabek J, Mojzita D, Novotny M, Puta F, Folk P. The SH3 domain of Src can downregulate its kinase activity in the absence of the SH2 domain-pY527 interaction. Biochem Biophys Res Commun. 2002; 296(3):664–70. Epub 2002/08/15. PMID: 12176033.

58. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs. Hum Mutat. 2016; 37(3):235–41. Epub 2015/11/12. https://doi.org/10.1002/humu.22932 PMID: 26555599; PubMed Central PMCID: PMCPMC4752381.